BCBS-Tennessee 5‑FU TDM Coverage Update

Coverage Criteria for 5‑FU Therapeutic Drug Monitoring

Initial and dose‑adjustment TDM for 5‑FU

Covered when ALL of the following are met:

Primary coverage condition: Individual is undergoing intravenous 5‑fluorouracil (5‑FU) chemotherapy and therapeutic drug monitoring (TDM) is being used to aid in managing dose adjustment.AUC target cited as 20–30 mg·h·L where applicable

Policy statement: TDM to aid dose adjustment meets coverage criteria; target AUC range referenced in reimbursement text.

Guideline‑based coverage considerations

Guideline‑based considerations relevant to coverage decisions include:

CPIC recommendations: For DPYD poor metabolizers (activity score 0.5 or 0): strongly recommended to avoid 5‑FU; if no alternative exists, consider strongly reduced 5‑FU dose with early therapeutic drug monitoring. For DPYD intermediate metabolizers: reduce starting dose based on activity score followed by titration based on toxicity or therapeutic drug monitoring (if available).

Source: CPIC guidance (Amstutz et al., 2018).

French / STP-PT / GPCO guidance: Groups (STP-PT, GPCO, RNPGx, GPCO‑UNICANCER) recommend implementation of 5‑FU TDM to ensure adequate exposure and endorse DPD testing/considerations for FP‑based chemotherapy.

Lemaitre et al. 2018; Etienne‑Grimaldi et al. 2023 summaries.

EMA commentary: EMA recommends DPD testing (DPYD variants or uracilemia) before fluoropyrimidine (FP)‑based chemotherapy; DPYD genotype‑guided dose reduction is clinically validated whereas uracilemia is less validated; 5‑FU TDM is recommended in partial DPD‑deficient patients.

Etienne‑Grimaldi et al. 2023 summary of EMA position.

Uracil breath tests and dihydrouracil/uracil ratio testing of plasma, serum, or urine samples to aid in managing 5‑FU dose adjustment do not meet coverage criteria. This policy identifies these specific assays as not supported by sufficient published scientific literature to demonstrate clear clinical benefit for dose management in individuals receiving intravenous 5‑fluorouracil chemotherapy.

The National Institute for Health and Care Excellence (NICE) states that the My5‑FU assay should be recommended only for research purposes (not routine clinical use). The International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) notes that the uracil breath test 'does not help in determining the correct dose and is not recommended for clinical use.' These guidance statements inform the policy decision to limit coverage for these uracil‑based assays.

The cited reference materials include guideline documents and reviews but do not specify additional explicit exclusion conditions beyond the identified tests. No further clinical scenarios or patient subgroups are described in these citations that would alter the exclusion of uracil breath testing or dihydrouracil/uracil ratio testing for 5‑FU dose adjustment.

Use of uracil breath tests or dihydrouracil/uracil ratio testing for 5‑FU dose management is considered not meeting coverage criteria due to insufficient published scientific literature demonstrating that these tests are required and beneficial for diagnosis or treatment decisions in this context.

Guidance sources explicitly state that the uracil breath test is not helpful for dosing and is not recommended for clinical use; NICE limits the My5‑FU assay to research settings. These statements support the policy stance that such uracil‑based tests should not be used for routine clinical dose optimization of 5‑FU.

The remaining cited literature in the policy document is bibliographic and does not contain explicit 'not medically necessary' declarations for other tests; it serves as supporting evidence and background on therapeutic drug monitoring methods and related studies.

Initial Therapy Criteria

TDM during 5‑FU therapy

TDM performed during therapy: Therapeutic drug monitoring (measurement of plasma 5‑FU concentrations) is performed for patients receiving IV 5‑FU to guide dose adjustments toward a target AUC.AUC 20–30 mg·h·L

Reimbursement text references AUC target range 20–30 mg·h·L and states TDM has reduced toxicity and improved efficacy for IV 5‑FU.

Pre‑treatment DPYD testing

Pre‑treatment testing recommendations from guideline sources:

DPYD testing prior to FP therapy: EMA and guideline groups recommend DPD/DPYD testing before fluoropyrimidine‑based chemotherapy. Genotype testing of key DPYD variants is clinically validated and should guide dose reductions; uracilemia (phenotyping) is less validated.

CPIC and Etienne‑Grimaldi summaries (CPIC: genotype‑guided dose reductions; Etienne‑Grimaldi/EMA: recommends DPD testing).

Continuation and Follow-up Criteria

Continuation therapy / follow‑up TDM

CPIC guidance relevant to follow‑up and continuation:

Follow‑up TDM after genotype‑based dose reduction: Follow‑up therapeutic drug monitoring is recommended to avoid underdosing patients who had genotype‑based dose reductions and who tolerate higher doses; titrate dose based on toxicity or TDM.

Explicit CPIC recommendation described in reimbursement text: follow‑up TDM is recommended post‑genotype adjustment.

Provider Actions, Billing, and Documentation

Note

Authorization and Denial

No prior authorization is specified in this segment of the policy. There are no explicit prior authorization requirements or authorization/denial rules stated for therapeutic drug monitoring (TDM) of 5‑fluorouracil (5‑FU) in this section — determinations are expected to follow the policy criteria and applicable government policies.

No prior authorization specified in this segment.
No explicit authorization or denial rule present.

Documentation Required

Documentation and References

Providers should document medically necessary use of 5‑FU therapeutic drug monitoring and be prepared to reference supporting clinical literature when submitting claims or prior authorization requests under other payer rules. The policy includes provider‑facing references and links to clinical studies and guideline documents that may be useful for implementation and supporting coverage decisions.

References include clinical studies and provider resources (see citations).

Procedure and Billing Codes

Applicable CPT/HCPCS Procedure Codesmixed

S3722	Dose optimization by area under the curve (AUC) analysis, for infusional 5- fluorouracil.
80299	Quantitation of therapeutic drug, not elsewhere specified.
82542	Column chromatography, includes mass spectrometry, if performed (e.g., HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen.
83789	Mass spectrometry and tandem mass spectrometry (e.g., MS, MS/MS, MALDI, MS- TOF, QTOF), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen.

inv-10: Target 5‑FU AUC — 20-30 mg·h·L

Target AUC range20–30 mg·h·L

Context for targetRecommended for intravenous continuous‑infusion 5‑FU dosing to optimize treatment and relate exposure to efficacy/toxicity

Use in policyReferenced as the AUC target when TDM is used to manage dose adjustment

Definitions and Abbreviations

inv-24: 5‑FU — 5‑fluorouracil

Term5‑FU

Definition5‑fluorouracil (intravenous chemotherapeutic agent)

Clinical noteUsed as continuous infusion for multiple cancers; TDM has been studied to reduce toxicity and improve efficacy

inv-25: AUC — area‑under‑curve

TermAUC

DefinitionArea‑under‑curve

Usage noteUsed as exposure metric for pharmacokinetic assessments

Background and Evidence Summary

Background: 5‑Fluorouracil (5‑FU) is administered intravenously and has a narrow therapeutic index. The policy supports therapeutic drug monitoring (TDM) of plasma 5‑FU concentrations to guide dose adjustments for individuals receiving IV 5‑FU chemotherapy, while explicitly excluding certain uracil‑based phenotyping assays. Guideline reviews and published studies cited in this policy discuss AUC‑guided dosing approaches, clinical outcomes, and the limitations of uracil breath testing and related assays that informed the coverage determinations.

Step Therapy

Step	Requirement
1
Genotype‑guided dose reduction (per CPIC recommendations for DPYD intermediate/poor metabolizers) followed by therapeutic drug monitoring (TDM) to titrate dose — i.e., reduce starting dose based on DPYD activity score and perform follow‑up TDM to guide dose titration or early TDM if a strongly reduced dose is used for poor metabolizers.

Site of Care Considerations

Billing Rule

Infusion‑center / laboratory billing and site‑of‑care note

AUC analysis and laboratory quantitation/mass spectrometry assays for 5‑FU are performed in laboratories (LDTs) and billed using the listed procedure codes; these are laboratory‑based services rather than point‑of‑care.

Site‑of‑care note: assays are laboratory performed (infusion center patients require lab processing).
Bill using codes S3722, 80299, 82542, 83789 as applicable.

OpenPayer

Therapeutic Drug Monitoring for 5‑Fluorouracil